Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antidepressants and the developing nervous system.

× No keyword cloud information.

10 in total

Review 1. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review.

Authors: Cynthia M Nijenhuis; Peter G J ter Horst; Lolkje T W de Jong-van den Berg; Bob Wilffert
Journal: Br J Clin Pharmacol Date: 2012-01 Impact factor: 4.335

2. Benefits exceed risks of newer antidepressant medications in youth--maybe not.

Authors: W Z Potter
Journal: Clin Pharmacol Ther Date: 2009-10 Impact factor: 6.875

3. Benefits exceed risks of newer antidepressant medications in youth--maybe.

Authors: J S March; B Vitiello
Journal: Clin Pharmacol Ther Date: 2009-10 Impact factor: 6.875

4. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials.

Authors: H A Dewar; M F Oliver
Journal: Br Med J Date: 1971-12-25

Review 5. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses.

Authors: Cynthia M Nijenhuis; Peter G J ter Horst; Nienke van Rein; Bob Wilffert; Lolkje T W de Jong-van den Berg
Journal: Br J Clin Pharmacol Date: 2012-01 Impact factor: 4.335

6. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators.

Authors:
Journal: Lancet Date: 1984-09-15 Impact factor: 79.321

Review 7. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.

Authors: C L Harden; K J Meador; P B Pennell; W A Hauser; G S Gronseth; J A French; S Wiebe; D Thurman; B S Koppel; P W Kaplan; J N Robinson; J Hopp; T Y Ting; B Gidal; C A Hovinga; A N Wilner; B Vazquez; L Holmes; A Krumholz; R Finnell; D Hirtz; C Le Guen
Journal: Neurology Date: 2009-04-27 Impact factor: 9.910

Antidepressants and the developing nervous system.

Review 1. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review.

2. Benefits exceed risks of newer antidepressant medications in youth--maybe not.

3. Benefits exceed risks of newer antidepressant medications in youth--maybe.

4. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials.

Review 5. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses.

6. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators.

8. Selective publication of antidepressant trials and its influence on apparent efficacy.

9. Serotonin modulates behavioral reactions to unfairness.

10. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.